Dyne Therapeutics

At Dyne, everything we do starts with the people living with neuromuscular diseases. As we continue to advance therapies designed to deliver functional improvement, we’re growing our team with individuals who want their work to make a real difference. We are currently looking for talented professionals to fill the following key roles: ▪️Director, Clinical Quality Assurance ▪️Senior Director, DMD Scientific and Medical Education Lead ▪️Senior Director, Drug Substance Manufacturing ▪️Director, US Data and Advanced Analytics If you’re motivated by science, collaboration and impact, we invite you to explore our open roles and help shape what’s possible for the communities we aim to serve. Explore all opportunities: https://bit.ly/47GxrhM

We recently sat down with John Maraganore, founding CEO of Alnylam, for our first FORCEs in Biotech session of the new year. As expected, it proved to be an engaging deep dive into the persistence required to build a new class of medicine. John shared what it was like when the world began to give up hope on RNAi. His reflections on navigating those challenges was a powerful reminder for all of us at Dyne: The Delivery First Mindset: Solving the foundational technical hurdle of getting molecules where they need to go is what unlocks everything else. The "Chess Game": Building a company isn't linear. It’s a series of strategic decisions around the platform, programs and potential partnerships while scaling a culture that retains its "innovator soul." The Gift of Optimism: John highlighted optimism as a practical survival tool for every person in this industry. At Dyne, we’re on our own delivery mission: to provide functional improvement to people living with neuromuscular diseases. As we pursue our ambitious mission, we’ll apply John’s insights and lessons and continue to move urgently toward our first potential launch in 2027.

We’re looking forward to joining the Duchenne community for an upcoming webinar to discuss our recently announced DELIVER trial results for zeleciment rostudirsen (z-rostudirsen) in people with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The data show meaningful and sustained functional improvement and reinforce the potential of z-rostidursen to transform care for individuals with DMD. Visit Parent Project Muscular Dystrophy (PPMD) to register and join the conversation: https://bit.ly/4ajCt6z

As we advance zeleciment basivarsen (z-basivarsen) for the treatment of myotonic dystrophy type 1 (DM1), we’re pleased to share Japan’s Ministry of Health, Labour and Welfare has granted z-basivarsen Orphan Drug designation. This designation builds on similar recognition in the U.S. and Europe and underscores the potential of z-basivarsen to deliver functional improvement for people living with DM1. Read more: https://bit.ly/4qrGEDV

We were built to tackle one of biotech’s most significant challenges: delivering therapies that lead to meaningful, sustained functional improvement for patients. At the 44th Annual J.P. Morgan Healthcare Conference on January 14, CEO John Cox will share how Dyne’s clinically validated FORCE™ platform is advancing a pipeline of therapeutics for genetically driven neuromuscular diseases and enabling our transformation into a commercial-stage organization. Recent data from our DELIVER trial demonstrates FORCE’s ability to deliver therapeutic payloads resulting in functional improvement across multiple clinical measures in people with Duchenne amenable to exon 51 skipping. This progress reflects our commitment to addressing unmet needs in DMD and other neuromuscular diseases. Learn more: https://bit.ly/3LeMSI5 #JPM26 #JPM2026

This year marked important progress for Dyne and the neuromuscular disease community, highlighted most recently by positive topline results from the DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy (DMD). We also advanced our myotonic dystrophy type 1 program, sharing data at the World Muscle Society including patient- and physician-reported outcomes that reflect improvements in function, strength and overall disease burden. We are proud of how far we have come, grateful for the support of the patient communities we serve and motivated by what lies ahead. As we close out the year, we wish everyone a safe and healthy holiday season.

We’re pleased to welcome Collegium President and CEO Vikram Karnani to our Board of Directors. Vikram brings deep commercial and executive leadership experience in rare disease and biopharmaceuticals, including nearly a decade at Horizon Therapeutics. His proven track record in launching products and driving growth will be invaluable as we approach commercialization and expand our portfolio. Welcome, Vikram—we’re excited to have you join us at this pivotal moment for Dyne and the neuromuscular disease community! Read about the appointment: https://bit.ly/48Ube2M

This holiday season, our #Dynamos came together to support two incredible organizations in our local community. 🎁 We participated in The Wonderfund gift drive to help provide gifts to children for the holidays. 🥫 And through our partnership with HEALTHY WALTHAM, we collected food items and essential toiletries to help local families in need. We’re grateful to everyone who donated and volunteered to make these drives a success, and to these organizations for their year-round commitment to children and families in our community.

A historic milestone for the Duchenne community. The addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel marks a major step toward earlier and broader diagnosis and timely intervention for children and families. This achievement reflects years of tireless advocacy and collaboration led by resilient families and dedicated organizations. We are honored to stand alongside Parent Project Muscular Dystrophy, and the Muscular Dystrophy Association as we work to deliver meaningful functional improvement for people living with neuromuscular diseases. Thank you to U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSAgov), HHS and the Duchenne community for your perseverance and unwavering hope. https://bit.ly/44r94oQ

We’ll be at the Pacifichem 2025, where Oxana Beskrovnaya, Dyne’s Chief Innovation Officer, will share how the FORCE™ platform was designed to deliver targeted therapeutics to muscle and CNS to provide functional improvement for people with neuromuscular diseases. Learn more and register: https://bit.ly/4s1n16Q